Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year

CONCLUSIONS: Super-responders treated with adalimumab have a higher rate of being female and fewer comorbidities. And super-responders have better PASI responses than non-super-responders, whether the patients were treated with adalimumab or switched to IL-17A inhibitors.PMID:38513258 | DOI:10.1080/09546634.2024.2331782
Source: Journal of Dermatological Treatment - Category: Dermatology Authors: Source Type: research